Cassava Sciences (STU:PX91) ROCE % : -67.76% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Cassava Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cassava Sciences's annualized ROCE % for the quarter that ended in Sep. 2024 was -67.76%.

Cassava Sciences ROCE % Historical Data

The historical data trend for Cassava Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences ROCE % Chart

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-24.03

-11.65

-19.33

-34.33

-56.97

Cassava Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-67.22	-61.60	-73.96	-184.11	-67.76

Cassava Sciences ROCE % Calculation

Cassava Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-97.163	/	( ( (221.683 - 6.667)	+	(139.075 - 13.017) )	/ 2 )
	=	-97.163	/	( (215.016	+	126.058)	/ 2 )
	=	-97.163	/	170.537
	=	-56.97 %

Cassava Sciences's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-110.364	/	( ( (226.275 - 50.718)	+	(201.601 - 51.388) )	/ 2 )
	=	-110.364	/	( ( 175.557	+	150.213 )	/ 2 )
	=	-110.364	/	162.885
	=	-67.76 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Cassava Sciences (STU:PX91) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cassava Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (STU:PX91) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SAVA:USA SAVA:Mexico PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Cassava Sciences Headlines

No Headlines